said its experimental head-and-neck cancer drug ispinesib failed a clinical trial in which it was meant to reduce or eliminate tumors. Cytokinetics shares were losing 14 cents, or 2.2%, to $6.21.
( ALTH) rose after the company said the Food and Drug Administration granted its lymphoma drug PDX fast-track review status. The stock was up 4% to $3.89.
is selling its transfusion business for $540 million to a group that includes private equity firm Texas Pacific. Shares of Baxter were up 6 cents at $45.24.
Heart-device makers' stocks were mixed after Merrill Lynch medical technology analyst Katherine Owen issued a number of ratings changes. The analyst downgraded
to neutral and
to sell. She reiterated her buy rating on
Johnson & Johnson
St. Jude Medical
, which separately announced that its chronic-pain neurostimulation system received regulatory and reimbursement approval in Australia, was upgraded to buy. Abbott's shares lost 1.3% to $47.61, Boston Scientific was 1.2% lower, trading at $14.50, St. Jude's stock gained 3% to $36.45, and J&J's shares were up 0.3% to $65.29.
Other health stocks on the move included
, 1.4% higher to $71.26,
, up 1.5% to $15.45,
( MOGN) gaining 2.5% to $17.36,
rising 4.9% to $23.59,
( SKYE), whose shares were boosted 10.4% to $5, and
( VIAC), up 4.5% to $4.55.
( BRL) lost 1.5% to $51.37,
traded 5.8% lower to $10.37,
fell 4.1% to $11.11,
lost 6.1% to $6.30, and
( DIL) shares were off 6.5% to $3.73.